{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021222","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.514527+00:00","generated_at":"2026-06-22T11:47:15.536969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023","bullets":["Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.","FY 2022 NUPLAZID guidance narrowed to $510-520M from $510-540M; R&D and SG&A guides trimmed.","FDA accepted trofinetide NDA for Rett syndrome with priority review; PDUFA action date March 12, 2023.","President Serge Stankovic to retire at year-end; search ongoing. Adora Ndu appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021222","json":"https://secwatch.observer/filing/0000950170-22-021222.json","markdown":"https://secwatch.observer/filing/0000950170-22-021222.md","text":"https://secwatch.observer/filing/0000950170-22-021222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/0000950170-22-021222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/acad-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:47:15.536969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1d8a15ba06a0fca1fd95a3a16cf01511386741f","claim":"ACADIA PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $130.7 million, net income $(0.17) per common share, EPS $(0.17) per common share. Guidance lowered.","evidence_excerpt":"Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022. NUPLAZID delivered net sales of $130.7 million in the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/0000950170-22-021222-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$130.7 million"},{"label":"Net income","value":"$(0.17) per common share"},{"label":"EPS","value":"$(0.17) per common share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}